July 6 (Reuters) - Endo International Plc said it would voluntarily remove its long-lasting opioid painkiller, Opana ER, a month after the U.S. Food and Drug Administration’s withdrawal request amid the growing opioid abuse crisis in the United States.
Endo’s shares fell 2.6 percent to $11.09 in afternoon trading on Thursday.
The company expects to incur a pre-tax impairment charge of about $20 million in the second quarter, Endo said.
Opana ER generated sales of about $159 million in 2016. (Reporting by Divya Grover in Bengaluru; Editing by Martina D‘Couto)